Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer

Oncology Letters

Volumn 2, Issue 3, 2011, Pages 493-498

  Kuboki, Yasutoshi ^a   Mizunuma, Nobuyuki ^a   Ozaka, Masato ^a   Ogura, Mariko ^a   Suenaga, Mitsukuni ^a   Shinozaki, Eiji ^a   Matsusaka, Satoshi ^a   Chin, Keishou ^a   Matsuura, Masaaki ^b   Hatake, Kiyohiko ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

Colorectal cancer; Elder; FOLFIRI

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CONTROL; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC PATIENT; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; TREATMENT DURATION; TREATMENT FAILURE; VOMITING;

EID: 79953268460     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.260     Document Type: Article

References (30)

1. Gatta G, Faivre J, Capocaccia R and Ponz de Leon M: Survival of colorectal cancer patients in Europe during the period 1978-1989. Eur J Cancer 34: 2176-2183, 1998.
2. Grothey A, Sargent D, Goldberg RM and Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209-1214, 2004.
3. Kelly H and Goldberg RM: Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23: 4553-4560, 2005.
4. Ho C, Ng K, O'Reilly S and Gill S: Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis. Clin Colorectal Cancer 5: 279-282, 2005.
5. Ferrucci L, Guralnik JM, Cavazzini C, Bandinelli S, Lauretani F, Bartali B, Repetto L and Longo DL: The frailty syndrome: a critical issue in geriatric oncology. Crit Rev Oncol Hematol 46: 127-137, 2003.
6. Walston J, Hadley EC, Ferrucci L, Guralnik JM, Newman AB, Studenski SA, Ershler WB, Harris T and Fried LP: Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on frailty in older adults. J Am Geriatr Soc 54: 991-1001, 2006.
7. Sawhney R, Sehl M and Naeim A: Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J 11: 449-460, 2005.
8. Sehl M, Sawhney R and Naeim A: Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J 11: 461-473, 2005.
9. Given B, Given C, Azzouz F and Stommel M: Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. Nurs Res 50: 222-232, 2001.
10. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF and Francini G: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345: 1091-1097, 2001.
11. Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E and Sargent DJ: Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24: 4085-4091, 2006.
12. Sastre J, Marcuello E, Masutti B, Navarro M, Gil S, Antón A, Abad A, Aranda E, Maurel J, Valladares M, Maestu I, Carrato A, Vicent JM, Díaz-Rubio E and Cooperative Group for the Treatment of Digestive Tumors: Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 23: 3545-3551, 2005.
13. Souglakos J, Pallis A, Kakolyris S, Mavroudis D, Androulakis N, Kouroussis C, Agelaki S, Xenidis N, Milaki G and Georgoulias V: Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Oncology 69: 384-390, 2005.
14. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D and Hecht JR: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21: 807-814, 2003.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
16. Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C and Herait P: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418, 1998.
17. Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, Maughan TS, Van Cutsem E, Rougier P, Mitry E, Schubert U and Köhne CH: Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2.691 patients in randomized controlled trials. J Clin Oncol 26: 1443-1451, 2008.
18. Feliu J, Salud A, Escudero P, Lopez-Gómez L, Bolanos M, Galán A, Vicent JM, Yubero A, Losa F, De Castro J, de Mon MA, Casado E and González-Barón M: XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 94: 969-975, 2006.
19. Au HJ, Mulder KE and Fields AL: Systematic review of management of colorectal cancer in elderly patients. Clin Colorectal Cancer 3: 165-171, 2003.
20. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.
21. Balducci L and Extermann M: Management of cancer in the older person: a practical approach. Oncologist 5: 224-237, 2000.
22. JS Macdonald: Vive la difference: gender and fluorouracil toxicity. J Clin Oncol 20: 1439-1341, 2002.
23. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J and Burris HA III: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26: 2311-2319, 2008.
24. Chau I, Norman AR, Cunningham D, Waters JS, Topham C, Middleton G, Hill M, Ross PJ, Katopodis R, Stewart G and Oates JR: Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 91: 1453-1458, 2004.
25. Bouchahda M, Macarulla T, Spano JP, Bachet JB, Lledo G, Andre T, Landi B, Tabernero J, Karaboué A, Domont J, Levi F and Rougier P: Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol 67: 255-262, 2008.
26. *28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2: 43-47, 2002.
27. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE and Ratain MJ: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22: 1382-1388, 2004.
28. *28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24: 3061-3068, 2006.
29. Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R, Ficarelli R, Fontana A, Andreoni F, Falcone A, Canestrari E, Tonini G, Mari D, Lippe P, Pizzagalli F, Schiavon G, Alessandroni P, Giustini L, Maltese P, Testa E, Menichetti ET and Magnani M: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 8: 278-288, 2008.
30. Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A and Toffoli G: Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 27: 457-465, 2009.